Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annu...(bility of VeraTagtechnology and the HERm...)

Date:5/16/2008

bility of VeraTag technology and the HERmark assay to predict response to Herceptin or to significantly improve the information available to physicians, results of studies intended to demonstrate clinical utility of HERmark, and potential commercialization of the HERmark assay. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: risks and uncertainties relating to the performance of our products, including HERmark; the growth in revenues; the risk that our VeraTag assays, including HERmark may not predict response to Herceptin or other therapeutic agents; the risk that we may not be able to obtain additional cohorts of patient samples for additional VeraTag studies, our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; actual market acceptance of our products for patient use and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applicat
'/>"/>

SOURCE Monogram Biosciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
2. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
3. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
4. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
5. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
6. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
7. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
8. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
9. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
10. Monogram Announces Third Quarter 2007 Financial Results
11. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call